JP2015504073A5 - - Google Patents

Download PDF

Info

Publication number
JP2015504073A5
JP2015504073A5 JP2014551387A JP2014551387A JP2015504073A5 JP 2015504073 A5 JP2015504073 A5 JP 2015504073A5 JP 2014551387 A JP2014551387 A JP 2014551387A JP 2014551387 A JP2014551387 A JP 2014551387A JP 2015504073 A5 JP2015504073 A5 JP 2015504073A5
Authority
JP
Japan
Prior art keywords
peptide
composition
amino acid
medicament
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014551387A
Other languages
English (en)
Japanese (ja)
Other versions
JP6416627B2 (ja
JP2015504073A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/020498 external-priority patent/WO2013106273A2/en
Publication of JP2015504073A publication Critical patent/JP2015504073A/ja
Publication of JP2015504073A5 publication Critical patent/JP2015504073A5/ja
Application granted granted Critical
Publication of JP6416627B2 publication Critical patent/JP6416627B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014551387A 2012-01-09 2013-01-07 ペプチドおよびその使用法 Active JP6416627B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261584517P 2012-01-09 2012-01-09
US61/584,517 2012-01-09
US201261699571P 2012-09-11 2012-09-11
US61/699,571 2012-09-11
PCT/US2013/020498 WO2013106273A2 (en) 2012-01-09 2013-01-07 Peptides and methods of using same

Publications (3)

Publication Number Publication Date
JP2015504073A JP2015504073A (ja) 2015-02-05
JP2015504073A5 true JP2015504073A5 (enExample) 2016-02-25
JP6416627B2 JP6416627B2 (ja) 2018-10-31

Family

ID=47595077

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014551387A Active JP6416627B2 (ja) 2012-01-09 2013-01-07 ペプチドおよびその使用法

Country Status (10)

Country Link
US (6) US9951104B2 (enExample)
EP (2) EP2802338B1 (enExample)
JP (1) JP6416627B2 (enExample)
AU (3) AU2013208293B2 (enExample)
CA (2) CA3077804C (enExample)
DK (2) DK3381461T3 (enExample)
ES (2) ES2676028T3 (enExample)
IL (1) IL233481A0 (enExample)
MX (1) MX365403B (enExample)
WO (1) WO2013106273A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2676028T3 (es) 2012-01-09 2018-07-16 Serpin Pharma, Llc Péptidos y procedimientos de uso de los mismos
WO2014197524A2 (en) * 2013-06-06 2014-12-11 Serpin Pharma, Llc Peptide therapy for treatment of alpha-1 antitrypsin deficiency and associated pathologies
EP4219534A3 (en) 2013-07-08 2023-09-27 The University of Utah Research Foundation Methods for treatment of and prophylaxis against inflammatory disorders
IL295025A (en) * 2014-09-16 2022-09-01 Bioincept Llc Preparations and methods for the treatment of acute radiation syndrome
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
EP3265064A4 (en) * 2015-03-04 2018-11-07 Microvention, Inc. Drug delivery device
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
BR112018003928A2 (pt) * 2015-08-28 2018-09-25 Serpin Pharma Llc métodos para o tratamento de doenças
WO2017083433A1 (en) * 2015-11-09 2017-05-18 Cortexyme, Inc. Inhibitors of arginine gingipain
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11447525B2 (en) 2018-05-02 2022-09-20 Niigata University Peptide and use therefor
EP4003391A4 (en) 2020-07-06 2023-02-22 Serpin Pharma, LLC PEPTIDES AND THEIR METHODS OF USE

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1190891B (it) 1982-06-24 1988-02-24 Anic Spa Metodo per la sintesi in fase solida di polipeptidi retroinvertiti
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
FI81498C (fi) 1987-01-13 1990-11-12 Biocon Oy Kirurgiska material och instrument.
US5580561A (en) * 1987-03-06 1996-12-03 Cercek; Boris Methods and pharmaceutical compositions for blocking suppression of immune defense mechanisms using an antibody, a factor, or an antisense peptide
US5270171A (en) * 1987-03-06 1993-12-14 Boris Cercek Cancer-associated SCM-recognition factor, preparation and method of use
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5981276A (en) 1990-06-20 1999-11-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US5353535A (en) 1990-11-05 1994-10-11 Plumly George W Floor type advertising apparatus
KR950702839A (ko) 1992-08-27 1995-08-23 스티븐 딕 레트로, 인버소-, 및 레트로- 인버소 합성 펩티드 유사체(retro-, inverso-, and retro-inverso synthetic peptide analogues)
EP1132080A3 (en) 1992-09-10 2001-10-17 Children's Medical Center Corporation Biodegradable polymer matrices for sustained delivery of local anesthetic agents
EP1024198A3 (en) 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
US5514653A (en) * 1994-09-09 1996-05-07 Washington University Method of blocking the SEC receptor
US5665557A (en) 1994-11-14 1997-09-09 Systemix, Inc. Method of purifying a population of cells enriched for hematopoietic stem cells populations of cells obtained thereby and methods of use thereof
WO1997014809A2 (en) 1995-10-16 1997-04-24 Dana-Farber Cancer Institute Novel expression vectors and methods of use
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
WO1999055564A1 (en) 1998-04-24 1999-11-04 Univ Florida Materials and methods for gene therapy
US20100210528A1 (en) * 1999-03-05 2010-08-19 Leland Shapiro Compositions, methods and uses for inhibition and/or treatment of influenza infection
AU2003221745A1 (en) 2002-04-19 2003-11-03 University Of Florida rAAV VECTOR-BASED COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MAMMALIAN DISEASES
WO2005019434A2 (en) 2003-08-26 2005-03-03 The Regents Of The University Of Colorado, A Body Corporate Serine protease inhibitors for treatment of bacterial infections
WO2005070445A2 (en) 2004-01-13 2005-08-04 Vasogenix Pharmaceuticals, Inc. Methods for treating acute myocardial infarction by calcitonin gene related peptide and compositions containing the same
DK1766412T3 (da) 2004-05-21 2009-05-25 Inst Systems Biology Sammensætninger og fremgangsmåder til kvantificering af serumglycoproteiner
US8715649B2 (en) 2005-06-07 2014-05-06 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods of use for alpha-1 antitrypsin having no significant serine protease inhibitor activity
KR20080085839A (ko) 2005-12-23 2008-09-24 바이탈 헬스 사이언시즈 피티와이 리미티드 사이토킨 조절 특성을 가진 화합물
US20110191871A1 (en) 2006-02-28 2011-08-04 Trustees Of Boston University Methods to identify factors associated with muscle growth and uses thereof
US20080008694A1 (en) 2006-07-05 2008-01-10 Elgebaly Salwa A Methods to prevent and treat diseases
US20100267052A1 (en) 2006-09-01 2010-10-21 American Type Culture Collection Compositions and methods for diagnosis and treatment of type 2 diabetes
US7951776B2 (en) 2006-09-01 2011-05-31 American Type Culture Collection Methods for treatment of type 1 diabetes
US20090203602A1 (en) * 2006-09-01 2009-08-13 Cohava Gelber Compositions and methods for diagnosis and treatment of type 2 diabetes
ES2651268T3 (es) 2006-09-12 2018-01-25 Beth Israel Deaconess Medical Center, Inc. Composiciones que contienen alfa-1-antitripsina y métodos para su uso
MY165889A (en) 2007-08-30 2018-05-18 Curedm Group Holdings Llc Compositions and methods of using proislet peptides and analogs thereof
US8758761B2 (en) 2007-09-30 2014-06-24 University Of Florida Research Foundation, Inc. Combination therapies for treating type 1 diabetes
US7923253B2 (en) * 2007-11-05 2011-04-12 Battelle Memorial Institute Method for identifying type I diabetes mellitus in humans
WO2011109768A2 (en) 2010-03-04 2011-09-09 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for modulating cardiac conditions
WO2011126882A2 (en) * 2010-03-30 2011-10-13 American Type Culture Collection Therapeutic peptides and their derivatives and therapeutic uses thereof
US9005615B2 (en) 2010-05-06 2015-04-14 The Feinstein Institute For Medical Research Methods for treatment of inflammatory diseases
ES2676028T3 (es) 2012-01-09 2018-07-16 Serpin Pharma, Llc Péptidos y procedimientos de uso de los mismos
KR20140137347A (ko) 2012-01-10 2014-12-02 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도
WO2014197524A2 (en) 2013-06-06 2014-12-11 Serpin Pharma, Llc Peptide therapy for treatment of alpha-1 antitrypsin deficiency and associated pathologies
KR20160146242A (ko) 2015-06-12 2016-12-21 현대자동차주식회사 터보차저 엔진의 재순환 밸브 구동 장치 및 방법
BR112018003928A2 (pt) 2015-08-28 2018-09-25 Serpin Pharma Llc métodos para o tratamento de doenças

Similar Documents

Publication Publication Date Title
JP2015504073A5 (enExample)
Verstockt et al. IL-12 and IL-23 pathway inhibition in inflammatory bowel disease
JP2018162295A (ja) 医薬製剤
Kamei et al. Determination of the optimal cell-penetrating peptide sequence for intestinal insulin delivery based on molecular orbital analysis with self-organizing maps
US20130281377A1 (en) Treating multiple myeloma
KR20100020516A (ko) Glp-1-fc 융합 단백질 제제
EA025663B1 (ru) Композиции этанерцепта, стабилизированные ионами металлов
JP2019533722A5 (enExample)
CN1812808A (zh) 稳定化的药物肽组合物
JP2014513952A5 (enExample)
CN111542335A (zh) 炎症性肠病的治疗药
Prachayakul et al. Factors influencing clinical outcomes of Histoacryl® glue injection-treated gastric variceal hemorrhage
Galipeau Mesenchymal stromal cells for graft-versus-host disease: a trilogy
Ding et al. Hemodynamic effects of continuous versus bolus infusion of terlipressin for portal hypertension: a randomized comparison
JP2019520316A5 (enExample)
JP2015508771A5 (enExample)
JP2020502150A5 (enExample)
JP2020502140A5 (enExample)
CA3249297A1 (en) Oxyntomodulin peptide analog formulations
CN110650747A (zh) 用于治疗慢性肾病的杜拉鲁肽
JP2017500316A5 (enExample)
Wu et al. Glucagon-like peptide-2-loaded microspheres as treatment for ulcerative colitis in the murine model
Dauvergne et al. Renal diseases secondary to interferon-β treatment: a multicentre clinico-pathological study and systematic literature review
JP2014504601A5 (enExample)
JP2014519514A5 (enExample)